<DOC>
	<DOCNO>NCT02146651</DOCNO>
	<brief_summary>The addition BioChaperone insulin lispro may accelerate onset shorten duration action insulin lispro due facilitation absorption insulin subcutaneous injection . The aim trial investigate dose-response dose-exposure relationship BioChaperone insulin lispro 3 dos , compare pharmacokinetics glucodynamic action BioChaperone insulin lispro 0.2U/Kg Humalog® 0.2 U/Kg ass safety tolerability BioChaperone insulin lispro Humalog® . This double-blinded , randomised , four-period crossover phase 2 trial use automate 12-hour euglycemic clamp subject type 1 diabetes mellitus . Each subject randomly allocate sequence 4 treatment , i.e . one three single dose BioChaperone insulin lispro ( 0.1 , 0.2 0.4 U/Kg ) one single dose Humalog® ( 0.2 U/Kg ) 4 separate dose visit .</brief_summary>
	<brief_title>A Double-blinded , Randomised , Four-period Crossover Euglycemic Clamp Trial Investigating Dose-response Dose-exposure Relationship BioChaperone Insulin Lispro Three Different Doses Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Type 1 diabetes mellitus least 12 month Treated multiple daily insulin injection insulin pump least 12 month Body Mass Index ( BMI ) : 18.528.0 Kg.m² Type 2 diabetes mellitus Receipt investigational product within 3 month prior first dose Clinically significant abnormality judge investigator Any systemic treatment drug know interfere glucose metabolism History alcoholism drug/chemical abuse per investigator 's judgement Use tobacco nicotinecontained product within 1 year prior screen Blood plasma donation past month 500ml within 3 month prior screen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>